Dualogics generates bispecific antibodies from any two existing antibody sequences.

Dualogics developed a platform called OrthoMab that consists of a collection of antibody mutations clustered in two regions of the antibody scaffold causing their antibody’s two heavy chains to correctly assemble into a single molecule. The OrthoMab technology allows for generation of a wide variety of bispecific formats that can be tailored to address the unique requirements dictated by target and disease biology.